US › Healthcare

Insmed Inc (INSM)

US · Healthcare · Biotechnology

$98.75+0.30%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$306.0M
Revenue YoY
+229.6%
Net profit
$-163.6M
Profit YoY
+36.3%
EPS
$-0.76
EPS estimate
$-1.00
Net margin
-53.5%

EPS came in at -0.76 against a street estimate of -1.00 — a beat of 24.0%.

Key statistics

Market cap
$21.34B
Forward P/E
16.4
P/B
30.32
Book value
$3.25
EPS (TTM)
$-5.76
52-week high
$212.75
52-week low
$90.39
50-day MA
$104.88
200-day MA
$147.61
Beta
0.79

Analyst view

Analysts rate Insmed Inc a strong buy (21 buy, 0 hold, 0 sell out of 21) with an average price target of $196.18.

Shareholding

Insiders
0.52%
Institutions
105.96%

Largest institutional holders

FundStake
JPMorgan Chase & Co11.14%
Darwin Global Management, Ltd.7.75%
BlackRock Inc7.69%
FMR Inc6.07%
Vanguard Portfolio Management, LLC4.79%
Vanguard Capital Management, LLC4.45%
Baker Bros Advisors LP3.42%
Artisan Partners Limited Partnership3.01%

Recent filings & reports

DocumentDate
Reg FD disclosure · Q3 20262026-07-16
Shareholder vote results · Q2 20262026-05-15
Results announced · Q2 20262026-05-07
Quarterly report · Q1 20262026-05-07
Reg FD disclosure · Q2 20262026-04-07
Proxy statement · Q2 20262026-04-01
Annual report FY20252026-02-19
Quarterly report · Q3 20252025-10-30

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Insmed Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.